SCHEMBL4813894

SCHEMBL4813894

CCCCCCCC/C=C\CCCCCCCCOCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CSCCCCCCCCCCCCCC

nearest known ligand 0.64

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 3/20 0.61
PRKCE Q02156 2/20 0.61
PRKCQ Q04759 2/20 0.61
PRKCD Q05655 2/20 0.61
ALDH1A1 P00352 1/20 0.55
LMNA P02545 1/20 0.55
ENPP2 Q13822 2/20 0.51
DGKA P23743 1/20 0.51
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
LPAR3 Q9UBY5 1/20 0.50
SELP P16109 1/20 0.49
LPAR1 Q92633 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5944349 0.94 PRKCA (0.67) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL5944344 0.91 PRKCA (0.63) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL4812483 0.89 ALDH1A1 (0.52) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL18789084 0.89 PRKCA (0.76) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL895900 0.89 PRKCA (0.76) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL13774342 0.89 PRKCA (0.76) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL18789085 0.89 PRKCA (0.76) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL18675509 0.89 PRKCA (0.76) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL5959980 0.89 PRKCA (0.57) PRKCAPRKCEPRKCQPRKCDALDH1A1
SCHEMBL18789083 0.89 PRKCA (0.76) PRKCAPRKCEPRKCQPRKCDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1596845-A1 THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF Genfit (FR) 2005-11-23 EP claimed
WO-2004073698-A1 THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF GENFIT (FR) 2004-09-02 WO claimed
US-7375135-B2 Fatty acid derivatives; preparation and uses thereof GENFIT (FR) 2008-05-20 US disclosed
EP-1673338-B1 FATTY ACID COMPOUNDS, PREPARATION AND USES THEREOF GENFIT (FR) 2007-09-19 EP disclosed
US-20060252827-A1 Therapeutic use of of acyglycerols and the nitrogen-and sulphur-containing analogues thereof GENFIT (FR) 2006-11-09 US disclosed
EP-1673338-A1 FATTY ACID COMPOUNDS, PREPARATION AND USES THEREOF Genfit (FR) 2006-06-28 EP disclosed
EP-1596845-A1 THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF Genfit (FR) 2005-11-23 EP disclosed
US-20040192908-A1 Fatty acid compounds, preparation and uses thereof GENFIT (FR) 2004-09-30 US disclosed
WO-2004073698-A1 THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF GENFIT (FR) 2004-09-02 WO disclosed
WO-2003014073-A1 FATTY ACID COMPOUNDS, PREPARATION AND USES THEREOF GENFIT (FR) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252827-A1 Therapeutic use of of acyglycerols and the nitrogen-and sulphur-containing analogues thereof SGMS2, SGMS1, AGK PRKCA 2280/4885PRKCE 2106/4885PRKCQ 1492/4885
US-20040192908-A1 Fatty acid compounds, preparation and uses thereof FASN, FFAR1, PLIN5 PRKCA 574/4885PRKCE 1014/4885PRKCQ 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.